DFN-02 is an intranasal spray formulation made up of sumatriptan 10mg and Aegis Therapeutics’ permeation-enhancing technology Intravail. The drug had shown its ability to treat pain and associated
As per terms of the deal, MedImmune will exclusively develop bi-specific and multi-specific antibody products derived from a Compugen pipeline program. The exclusive license will allow MedImmune to
The company said it will stop trial based on significant positive results from interim analysis. According to the company, the MN-001 significantly reduced mean serum triglycerides, which is a
Redx said it communicated with the Medicines and Healthcare products Regulatory Agency (MHRA) to interrupt the clinical trial of the Porcupine inhibitor. The company detected significant adverse events
Takeda announced that its consideration of such an offer is at a preliminary and exploratory stage and no approach has been made to the board of Shire. Shire
Pedmark, a formulation of sodium thiosulfate (STS), is a water-soluble thiol compound that serves as a chemical reducing agent. Delayed administration (between four to eight hours) of high dose
In 2015, the consumer healthcare JV was established, as part of a three-part inter-conditional transaction between GSK and Novartis. The JV is a combination of Novartis' over-the-counter (OTC)
Vobarilizumab is the firm’s anti-IL-6R Nanobody, which did not achieve the primary endpoint of dose response based on the modified BILAG-based combined lupus assessment (mBICLA) at week 24.
The Phase III IMpower150 study has achieved its co-primary endpoint of overall survival (OS) at the interim analysis and demonstrated that combined lung cancer treatment helped people with
The trial assessing the efficacy and safety of vareniclin for smoking cessation in nicotine dependent adolescents between 12 years and 19 years of age did not achieve its
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.